AnaptysBio (NASDAQ:ANAB) Given Outperform Rating at Wedbush

Wedbush restated their outperform rating on shares of AnaptysBio (NASDAQ:ANAB) in a research report released on Thursday,RTT News reports. The firm currently has a $42.00 price target on the biotechnology company’s stock.

Several other analysts also recently commented on ANAB. HC Wainwright reduced their price objective on shares of AnaptysBio from $55.00 to $52.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Guggenheim upped their price objective on shares of AnaptysBio from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Truist Financial upped their price objective on AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a research note on Thursday, August 15th. JPMorgan Chase & Co. reduced their price objective on AnaptysBio from $75.00 to $66.00 and set an “overweight” rating for the company in a report on Tuesday. Finally, UBS Group boosted their target price on AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a research note on Wednesday, October 30th. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, AnaptysBio currently has a consensus rating of “Moderate Buy” and a consensus target price of $54.64.

AnaptysBio Trading Down 3.4 %

ANAB stock traded down $0.69 during midday trading on Thursday, hitting $19.48. The stock had a trading volume of 109,060 shares, compared to its average volume of 348,333. The business has a fifty day moving average price of $31.40 and a two-hundred day moving average price of $29.89. AnaptysBio has a 1-year low of $13.36 and a 1-year high of $41.31. The firm has a market cap of $592.78 million, a P/E ratio of -3.19 and a beta of -0.24.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, beating the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The company had revenue of $30.02 million for the quarter, compared to analyst estimates of $7.92 million. On average, equities analysts anticipate that AnaptysBio will post -6.09 EPS for the current year.

Insider Transactions at AnaptysBio

In other news, insider Paul F. Lizzul sold 1,500 shares of the company’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $38.67, for a total value of $58,005.00. Following the completion of the transaction, the insider now directly owns 15,398 shares in the company, valued at approximately $595,440.66. This represents a 8.88 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Dennis Mulroy sold 12,220 shares of the stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $39.91, for a total value of $487,700.20. Following the transaction, the chief financial officer now owns 4,744 shares in the company, valued at $189,333.04. This trade represents a 72.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 22,440 shares of company stock valued at $892,936. 33.70% of the stock is currently owned by corporate insiders.

Institutional Trading of AnaptysBio

Hedge funds and other institutional investors have recently bought and sold shares of the company. Rhumbline Advisers lifted its holdings in shares of AnaptysBio by 1.8% in the 2nd quarter. Rhumbline Advisers now owns 29,715 shares of the biotechnology company’s stock worth $745,000 after acquiring an additional 525 shares during the last quarter. Algert Global LLC lifted its stake in AnaptysBio by 11.8% in the second quarter. Algert Global LLC now owns 10,178 shares of the biotechnology company’s stock worth $255,000 after purchasing an additional 1,078 shares during the last quarter. nVerses Capital LLC boosted its position in AnaptysBio by 700.0% during the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after buying an additional 1,400 shares during the period. Values First Advisors Inc. bought a new position in shares of AnaptysBio during the third quarter valued at about $49,000. Finally, Allspring Global Investments Holdings LLC purchased a new position in shares of AnaptysBio in the first quarter worth about $38,000.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.